Theriva Biologics, Inc. (TOVX)

Theriva Biologics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	11.34	13.06	11.61	23.18	41.79	67.33
Cash & Short-Term Investments	11.34	13.06	11.61	23.18	41.79	67.33
Cash Growth	-6.46%	12.46%	-49.91%	-44.53%	-37.93%	981.18%
Other Receivables	1.81	3.84	3.32	1.94	0.23	-
Receivables	1.81	3.84	3.32	1.94	0.23	-
Prepaid Expenses	0.46	0.58	0.98	1.17	1.21	1.08
Other Current Assets	0.06	-	0.37	1.12	2.29	0.46
Total Current Assets	13.67	17.47	16.28	27.4	45.52	68.86
Property, Plant & Equipment	2	1.03	1.54	2.18	1.54	1.48
Goodwill	-	-	-	5.7	5.53	-
Long-Term Deferred Charges	19.06	19.62	17.36	19.76	19.15	-
Other Long-Term Assets	0.12	0.13	0.17	0.18	0.12	0.02
Total Assets	34.86	38.24	35.35	55.22	71.86	70.37

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	0.98	1.01	0.86	0.77	0.92	0.52
Accrued Expenses	6.71	6.72	4.51	4.51	2.9	2.91
Current Portion of Long-Term Debt	0.03	0.06	0.06	0.06	0.06	-
Current Portion of Leases	0.53	0.55	0.54	0.49	0.22	0.12
Other Current Liabilities	3.86	1.68	1.61	0.91	2.97	-
Total Current Liabilities	12.11	10.01	7.59	6.74	7.06	3.55
Long-Term Debt	1.62	1.67	0.09	0.16	0.22	-
Long-Term Leases	1.37	0.35	0.87	1.44	1.19	1.4
Long-Term Deferred Tax Liabilities	-	-	-	-	1.62	-
Other Long-Term Liabilities	7.57	10.82	7.74	7.18	7.21	-
Total Liabilities	22.67	22.86	16.29	15.52	17.3	4.96

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.05	0.03	0	0	0.02	0.01
Additional Paid-In Capital	376.15	373.59	355.5	346.54	343.75	336.68
Retained Earnings	-363.97	-358.71	-334.97	-309.32	-290.97	-271.28
Treasury Stock	-0.29	-0.29	-0.29	-0.29	-0.29	-
Comprehensive Income & Other	0.25	0.76	-1.18	0.03	-0.68	-
Total Common Equity	12.19	15.38	19.07	36.96	51.83	65.41
Shareholders' Equity	12.19	15.38	19.07	39.7	54.56	65.41
Total Liabilities & Equity	34.86	38.24	35.35	55.22	71.86	70.37

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	3.55	2.63	1.57	2.15	1.68	1.53
Net Cash (Debt)	7.78	10.43	10.04	21.02	40.11	65.8
Net Cash Growth	-15.66%	3.81%	-52.22%	-47.58%	-39.05%	1043.52%
Net Cash Per Share	0.25	0.86	7.45	32.63	65.41	134.97
Filing Date Shares Outstanding	45.89	45.89	2.78	0.69	0.6	0.63
Total Common Shares Outstanding	45.89	35.69	2.78	0.69	0.6	0.53
Working Capital	1.56	7.45	8.7	20.67	38.46	65.3
Book Value Per Share	0.27	0.43	6.85	53.89	85.67	123.84
Tangible Book Value	12.19	15.38	19.07	31.26	46.31	65.41
Tangible Book Value Per Share	0.27	0.43	6.85	45.58	76.54	123.84
Machinery	0.64	0.64	0.71	0.9	0.9	0.83
Leasehold Improvements	0.09	0.09	0.09	0.09	0.09	0.09

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 11, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 17, 2026

Data Sources Report a data error